开普拓5-FU/CF治疗晚期结直肠癌临床观察  

Clinical Observation on CPT-11 Combined with 5-FU/CF in Patients with Advanced or Metastatic Colorectal Cancer

作　　者：郭晓葵[1] 

机构地区：[1]苏州大学附属第二医院肿瘤科,苏州市215004

出　　处：《医药论坛杂志》2009年第12期4-6,共3页Journal of Medical Forum

摘　　要：目的观察CPT-11(开普拓)联合5-FU/CF治疗晚期结直肠癌的临床疗效和毒副反应。方法入组患者27例均为手术后局部复发和转移的晚期结直肠癌,经FOLFIRI方案化疗二个疗程(共4次)后,评价疗效,按照WHO实体瘤近期客观疗效评定标准进行评价。结果全组27例均可评价疗效及不良反应。完全缓解(CR)为0,部分缓解(PR)为6例(6/27),总有效率(CR+PR)达22%,疾病稳定(SD)16例(16/27)59.26%,疾病控制率(CR+PR+SD)为81.48%,疾病进展(PD)5例(5/27)18.52%。中位疾病进展时间为7.1个月(5～26个月),中位生存时间9.2个月。不良反应主要是消化道反应和骨髓抑制,以延迟性腹泻为多见,有8例为Ⅰ/Ⅱ度,Ⅲ/Ⅳ度仅1例,有4例Ⅰ/Ⅱ度骨髓抑制,Ⅲ/Ⅳ度骨髓抑制仅2例,无治疗相关的死亡。结论开普拓联合5-FU/CF治疗晚期结直肠癌近期疗效确切,不良反应可控制,临床上可大胆应用。Objective To observe the effect and toxicity of campto （ CPT - 11 ） combined with 5 - FU/CF in patients with advanced or metastatic colorectal cancer. Methods Twenty - seven patients with local recurrence after surgery and advanced or metastatic colorectal cancer were included to receive FOLFIRI regimen biweekly （ irinotecan 180mg/m^2 on dayl, 5 - FU 400mg/m^2 iv bolus on day1,2 and 600mg/m^2 iv continuous infusion 22 - hours on dayl ,2 with CF 200mg/m^2 administrated 2 - hour before 5 - FU infusion）. They were assessed on the basis of WHO evaluation standard of the objective therapeutic effect for solid tumor. Results 27 patients were assessable to observe the effect and safety. The case of CR, PR, SD, PD was respectively 0, 6, 16 and 5. So total response rate （CR ＋PR） was 22. 22% （6/27） and disease control rate （CR ＋ PR ＋ SD） was 81.48%. The median time to progression was 7. 1 months （5 to 26 months） and median overall survival time was 9. 2 months. The majority of toxicity was marrow suppression and gastrointestinal reaction. The delayed diarrhea was more common, which were mostly Ⅰ/Ⅱ degree（8/27） and only 1 case was Ⅲ/Ⅳ degree. 4 cases were Ⅰ/Ⅱ degree related death. Conclusion and 2 cases were Ⅲ/Ⅳ myelosuppression. There was no case of treatment - The biweekly regimen of irinotcan in combination with 5 - FU/CF results in significant and clinically meaningful improvement in survival and quality of life and its toxicity is manageable among patients with advanced or metastatic colorectal cancer.

关 键 词：晚期结直肠癌 开普拓(CPT-11) 化疗 

分 类 号：R735.3[医药卫生—肿瘤]